ACUTAASAcutaas Chemicals Limited
Chemicals · Specialty Chemicals · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Acutaas Chemicals Limited engages in the research and development, manufacture, and sale of pharmaceutical intermediates in India and internationally. The company offers pharma intermediates for use in regulated and generic active pharmaceutical ingredients for anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson's, antidepressant, and anticoagulant applications. It also provides specialty chemicals for use in battery chemicals, personal care, agrochemicals, coatings, electronics, and industrial processes; photoresist chemicals to semiconductor applications; electrolyte additives for lithium battery cells; and parabens, methyl salicylate, and other commodity chemicals for cosmetics, agrochemicals, and fine chemicals. The company was formerly known as Ami Organics Limited and changed its name to Acutaas Chemicals Limited in May 2025. Acutaas Chemicals Limited was founded in 2004 and is based in Surat, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
The picture
- • Revenue growth: 40.3% YoY
- • Profit growth: 105.6% YoY
- • ROE: 23.5%
- • RSI: 57
- • MACD: bullish
- • Price vs EMA21: above
- • Bollinger Squeeze signal (setup quality 78%)
- • Pullback to 21-EMA signal (setup quality 63%)
Bull case
- • Revenue growth: 40.3% YoY
- • Profit growth: 105.6% YoY
- • ROE: 23.5%
- • RSI: 57
Bear case
- • Valuation vs sector: P/E 95.8 vs sector 23.2
- • Dividend yield: 0.05%
- • Supertrend: bearish
- • Sector momentum: sector -10.3% (1m)
Key risks
- • Valuation vs sector: P/E 95.8 vs sector 23.2
- • Dividend yield: 0.05%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹126.88). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.